Please note that the contents in this webpage are current as of the date of the announcement and the information including but not limited to the product availability, specification, prices, contacts, are subject to change without prior notice.
- May 13, 2025
- FUJIFILM Toyama Chemical Applies for Manufacturing and Marketing Approval in Japan for FF-31501, an Autologous Synovial Mesenchymal Stem Cell-based Therapy
- Apr 16, 2024
- FUJIFILM Toyama Chemical and Synplogen Enter Strategic Business Alliance Agreement on CDMO Services for mRNA therapeutics, to Provide Seamless End-to-End Services from mRNA Sequence Design to LNP Formulation and Fill/Finish
- Feb 5, 2024
- TriLink BioTechnologies® and FUJIFILM Toyama Chemical Sign Non-exclusive License and Supply Agreement for CleanCap® mRNA capping technology
- Oct 14, 2022
- FUJIFILM Toyama Chemical discontinues development of “Avigan® Tablet” anti-influenza drug as a treatment for COVID-19 (Fujifilm)
- Oct 6, 2022
- Fujifilm to establish its first Bio-CDMO site in Japan (Fujifilm)